Back to News
Market Impact: 0.38
Vanda's HETLIOZ Meets Phase 3 Goal In Delayed Sleep-Wake Phase Disorder; Stock Up
Source: Nasdaq
Healthcare & Biotech
Vanda Pharmaceuticals reported positive topline results from a Phase 3 trial of HETLIOZ (tasimelteon) 20 mg in adults with Delayed Sleep-Wake Phase Disorder. The positive late-stage clinical result could support potential expansion of HETLIOZ's addressable market, although the article provided no efficacy data, regulatory timeline, or financial estimates.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.62
Ticker Sentiment
VNDA0.80
More News
- Walgreens owner nears $9 billion deal to sell Boots chain- WSJ
- Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial
- Lilly’s Foundayo shows cardiovascular safety in diabetes trial
- Some Oura IPO Investors Were Said to Push Back Citing Valuation
- Nvidia is approaching a breakout level. Plus, what we want to see from Micron
- Wall Street is closing out a strong quarter. Plus, Lilly's mixed obesity drug trial data
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Augmented Intelligence: AllMind, Elevate Human Judgement With an Accessible, Powerful, Data-Driven Financial AI Toolkit
- AI Research Systems for Hedge Funds: A Pilot Design